BridgeBio Pharma (NASDAQ: BBIO) net income
BridgeBio Pharma reported a net loss of $732.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $543.3m. Earnings per share were −$3.78.
BridgeBio Pharma's best year of the last 8 was fiscal 2018. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$732.9m | — | −146.0% | −$3.78 |
| 2024 | −$543.3m | — | −244.9% | −$2.88 |
| 2023 | −$653.3m | — | −7,021.9% | −$3.95 |
| 2022 | −$484.7m | — | −624.2% | −$3.26 |
| 2021 | −$586.5m | — | −841.2% | −$3.90 |
| 2020 | −$505.5m | — | −6,127.9% | −$3.80 |
| 2019 | −$288.6m | — | −711.5% | — |
| 2018 | −$169.5m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
BridgeBio Pharma net income compared with its sector
By net income for its latest fiscal year, BridgeBio Pharma ranks 485th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of BridgeBio Pharma, −146.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 483rd | Vor Biopharma | −$696.0m | — |
| 484th | Sarepta Therapeutics | −$713.4m | −32.5% |
| 485th | BridgeBio Pharma | −$732.9m | −146.0% |
| 486th | Biohaven | −$738.8m | — |
| 487th | Vaxcyte | −$766.6m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of BridgeBio Pharma
- How much did BridgeBio Pharma earn in fiscal 2025?
- BridgeBio Pharma reported a net loss of $732.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $543.3m.
- What are the earnings per share of BridgeBio Pharma?
- They were −$3.78 in fiscal 2025, compared with −$2.88 in fiscal 2024.
- Where does BridgeBio Pharma rank in its sector by net income?
- It ranks 485th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for BridgeBio Pharma come from?
- From the annual report (Form 10-K) that BridgeBio Pharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that BridgeBio Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on BridgeBio Pharma: the BridgeBio Pharma page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.